We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

162 hedge funds and large institutions have $2.42B invested in Blueprint Medicines in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 51 increasing their positions, 59 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more call options, than puts

Call options by funds: $10.1M | Put options by funds: $7M

1.84% more ownership

Funds ownership: 102.2% → 104.04% (+1.8%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

14% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 59

14% less funds holding

Funds holding: 188 → 162 (-26)

31% less capital invested

Capital invested by funds: $3.5B → $2.42B (-$1.08B)

62% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 37

Holders
162
Holders Change
-26
Holders Change %
-13.83%
% of All Funds
3.61%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
14
Increased
51
Reduced
59
Closed
37
Calls
$10.1M
Puts
$7M
Net Calls
+$3.1M
Net Calls Change
+$10.2M

Top Buyers

1
Viking Global Investors
Viking Global Investors
Connecticut
+$66.2M
2
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$16.6M
3
FCMI
Foresite Capital Management III
California
+$16.3M
4
Alkeon Capital Management
Alkeon Capital Management
New York
+$13.6M
5
American Century Companies
American Century Companies
Missouri
+$11.4M

Top Sellers

1
HIM
Hillhouse Investment Management
Cayman Islands
-$112M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$18.8M
3
Citadel Advisors
Citadel Advisors
Florida
-$12.3M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$9.6M
5
State Street
State Street
Massachusetts
-$9.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$355M +$571K +9,397 +0.1%
Vanguard Group
2
Vanguard Group
Pennsylvania
$206M +$5.02M +82,572 +2%
BlackRock
3
BlackRock
New York
$186M -$191K -3,144 -0.1%
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$163M +$8.37M +137,760 +5%
Wellington Management Group
5
Wellington Management Group
Massachusetts
$142M -$18.8M -309,658 -11%
O
6
OppenheimerFunds
New York
$91.9M +$2.21M +36,394 +2%
State Street
7
State Street
Massachusetts
$82.8M -$9.13M -150,176 -9%
PHS
8
PFM Health Sciences
California
$79.3M +$1.85M +30,398 +2%
HA
9
HHLR Advisors
Cayman Islands
$77.1M +$87M +1,430,949 New
Viking Global Investors
10
Viking Global Investors
Connecticut
$64.7M +$66.2M +1,089,222 +980%
TCM
11
TimesSquare Capital Management
New York
$54M -$2.39M -39,400 -4%
TGI
12
TRV GP II
Massachusetts
$47.4M – – –
AllianceBernstein
13
AllianceBernstein
Tennessee
$46.8M -$9.6M -157,952 -15%
PA
14
Perceptive Advisors
New York
$43.5M -$5.09M -83,821 -9%
Norges Bank
15
Norges Bank
Norway
$42.7M – – –
EAM
16
Eagle Asset Management
Florida
$41M -$1.06M -17,414 -2%
CC
17
Casdin Capital
New York
$34.5M -$6.69M -110,000 -15%
AG
18
Artal Group
Luxembourg
$32.3M +$6.08M +100,000 +20%
Westfield Capital Management
19
Westfield Capital Management
Massachusetts
$31.4M +$4.46M +73,446 +14%
BI
20
BVF Inc
California
$31M -$1.42M -23,300 -4%
CTA
21
Carillon Tower Advisers
Florida
$30.5M – – –
Lord, Abbett & Co
22
Lord, Abbett & Co
New Jersey
$28.9M +$7.55M +124,282 +30%
DM
23
Deerfield Management
New York
$28.1M -$243K -4,000 -0.8%
Northern Trust
24
Northern Trust
Illinois
$27.2M -$1M -16,508 -3%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$26.6M +$1.85M +30,499 +7%
1
2 3 4 5

BPMC Hedge Fund Activity: Q4 2018 in Review

162 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2018, worth a combined $2.42B — down 31% from $3.5B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of BPMC and 14 opened new positions — a net loss of 23 holders — while 59 trimmed existing stakes and 51 added.

The largest buyer was Viking Global Investors, adding an estimated $66.2M. The largest seller was Hillhouse Investment Management, exiting entirely with an estimated $112M sold.

  • 162 institutional investors held Blueprint Medicines (BPMC) as of Q4 2018, down from 188 in Q3 2018.
  • Funds reported $2.42B of Blueprint Medicines stock for Q4 2018, down 31% quarter-over-quarter.
  • 14 funds opened new Blueprint Medicines positions in Q4 2018 and 37 closed out, a net change of -23 holders.
  • The largest Blueprint Medicines buyer in Q4 2018 was Viking Global Investors, an estimated $66.2M added.
  • The largest Blueprint Medicines seller in Q4 2018 was Hillhouse Investment Management, an estimated $112M sold.

Based on aggregated 13F filings for Q4 2018.